Scholarships & Careers Hub’s Post

🔬 Banked #Biospecimens Available at #CBRS Biobank! Exciting news for researchers in the field of oncology! 🌟 CBRS Biobank is thrilled to announce the availability of a diverse range of banked biospecimens, with a special focus on cancer-related samples. ℹ️ Our biobank boasts an extensive collection of high-quality biospecimens meticulously curated to meet the diverse needs of cancer research. From tumor tissues to blood samples and beyond, we offer a comprehensive repository of biological materials for your investigative endeavors. 🔍 With a commitment to advancing #cancer research, CBRS Biobank provides access to a wide variety of disease-specific biospecimens, exclusively tailored to support studies in oncology. Whether you're exploring biomarkers, investigating therapeutic targets, or conducting genomic analyses, our banked biospecimens serve as invaluable resources to fuel your research endeavors. 💡 #Collaborate with us today and unlock the potential of our banked biospecimens to accelerate your cancer research initiatives. Together, let's pave the way for groundbreaking discoveries in the fight against cancer. 📩 For inquiries or to access our #banked biospecimens, please contact us at sales@clinicalbiosamples.com #CBRSBiobank #CancerResearch #BankedBiospecimens #Oncology #ResearchInnovation

🎓🧬Thesis Defense Completed! I'm thrilled to announce that I successfully defended my Master’s thesis, entitled: “Untargeted Metabolomics Analysis of Plasma Samples of Lung Cancer Patients for the Discovery of Diagnostic and Prognostic Biomarkers for Lung Cancer Utilizing UHPLC-tims-QToF-MS". In this project, I focused on leveraging untargeted metabolomics to identify potential metabolomic biomarkers in plasma samples of lung cancer patients, aiming to discover potential tools for early diagnosis and prognosis of NSCLC. My gratitude goes out to my supervisor Prof. Dr. Markou Athina as well as Prof.Dr. Gikas Evangelos and Dr. Panara Anthi for their guidance and mentorship, to my colleagues, and everyone who provided support and encouragement throughout this project! Looking forward to contributing further to the field of cancer research and exploring how metabolomics could be a powerful tool in cancer research! While this chapter is complete, the journey now truly begins!! #Metabolomics #CancerResearch #CancerMetabolomics #Biomarkers #LungCancer #NSCLC #UHPLCtimsQToFMS #LiquidBIopsy#Research

Could Wasp Venom Hold the Key to Fighting Cancer? It may sound like a plot twist from a science-fiction movie, but researchers are exploring wasp venom as a potential weapon against cancer! The venom of the Brazilian wasp (Polybia paulista), one of the most aggressive social wasps, contains a molecule known as MP1, which has shown an impressive ability to kill cancer cells—without harming healthy ones. MP1 works by creating tiny holes in the lipid membranes of cancer cells, causing vital molecules to leak out and ultimately killing the cell in seconds. This selective targeting could be a game-changer, as MP1 leaves normal cells unharmed, making it a promising candidate for future cancer treatments. And this isn’t the only venom in the spotlight! Scorpion venom is also being researched for its peptides, which can induce cell death in tumors. These findings remind us that some of nature’s most feared creatures may hold cures for our most feared diseases. Imagine a future where venom-derived treatments become mainstream in oncology! It’s a fascinating reminder that sometimes, solutions to complex problems can be found in the most unexpected places. #Bioinformatics #CancerResearch #Oncology #Biotechnology #WaspVenom #CancerTreatment #Innovation #MedicalResearch #LinkedInScience

🔍 Exploring the Ancient Foundations of Modern Cancer: A Game-Changer in Oncology? A fascinating study highlighted by the NCI reveals that a 30-million-year-old DNA fragment from an ancient retrovirus, LTR10, might be a pivotal player in cancer growth. Found to be active in numerous cancer types, LTR10 acts as an enhancer, turning on genes linked to cancer survival. Notably, in one-third of colorectal cancer patients, it's a major factor in disease progression. This discovery doesn't just add a layer to our understanding of cancer biology—it revolutionizes it. By regulating genes like XRCC4, which aid cancer survival post-radiation, LTR10 hints at groundbreaking therapeutic strategies. Imagine silencing these elements to boost treatment efficacy! The broader implication? Ancient DNA is rewriting our grasp of cancer's genetic architecture, highlighting untapped avenues for intervention. As we stand on the cusp of this new frontier, how might these insights reshape your approach to cancer treatment or research? Let's discuss! 💬 #CancerResearch #OncologyInnovation #RetrovirusInsights

Remember the microenvironment. CAFSs and Cancer Stem Cells both play a role in protecting tumors. Cancer stem cells can cause reoccurrence after remission. Check out related publications (https://lnkd.in/gGaJwVX), National Cancer Institute (NCI) NCI Division of Cancer Control and Population Sciences Neuromics David Rupp

🚨 Breaking Boundaries in Cancer Research: The Molecular Jackhammer! 🔬⚡ Researchers at Rice University have made a ground-shaking discovery, developing what they're calling a "molecular jackhammer" to crush cancer cells! This innovative approach uses vibrating molecules to smash the integrity of cancer cell membranes—destroying them with precision. 💥🧬 Using near-infrared light 🌟, the team activates specially designed aminocyanine molecules to vibrate like tiny jackhammers, targeting cancer cells while minimizing harm to healthy tissues. 🛡️ This method could be a game-changer for cancer therapy, offering less invasive, highly targeted treatments. 🎯 Could this be the future of cancer care? I’m excited to see how this new technology could shake up the landscape of cancer treatment! 🌍💪 #CancerResearch #Innovation #Biotech #MolecularMedicine #Oncology #MedicalBreakthroughs #RiceUniversity Read more: https://lnkd.in/ehGAjGvg

🌟 Exciting Research Update! 🌟 I am thrilled to share that my latest research article titled "One-Pot Multicomponent Synthesis of Novel Pyrazole-Linked Thiazolyl-Pyrazolines: Molecular Docking and Cytotoxicity Assessment on Breast and Lung Cancer Cell-lines" has been accepted in the prestigious Journal of Molecular Structure! Elsevier, IF=4.0, Q2 Journal 🎉 In this study, we explored an innovative, efficient one-pot synthesis of pyrazole-linked thiazolyl-pyrazolines and evaluated their potential against breast and lung cancer cell lines. The promising cytotoxicity results provide exciting leads for future cancer research. This publication comes as an added celebration, coinciding with the first day of Navratri, symbolizing new beginnings and breakthroughs. A huge thank you to my co-authors, collaborators, and all those who supported this work. 🙏 Your encouragement and insights were invaluable. Looking forward to further advancements in this field and hoping this research will make a positive impact in cancer therapeutics. 🌿 Dr. Suraj Mali Alkesh Patel Niyati Patel Mehul Patel Dr. Ronak kamani #Research #CancerResearch #MolecularDocking #Cytotoxicity #DrugDiscovery #Navratri #JournalOfMolecularStructure #InnovationInScience

Cancer cells may now be reverted back to normal healthy cells. This groundbreaking discovery from KAIST opens a new frontier in cancer research. A research team led by Professor Kwang-Hyun Cho developed an innovative technology to transform colon cancer cells into a state resembling normal cells, avoiding the harmful side effects of conventional therapies. By creating a “digital twin” of gene networks, the team systematically identified key molecular switches that enable normal cell differentiation. When applied to colon cancer cells, these switches triggered a remarkable reversion to a normal-like state—a result confirmed through cellular and animal studies. This breakthrough introduces the exciting concept of reversible cancer therapies, offering hope for safer and more effective treatment options. With its potential applications across multiple cancer types, this milestone marks a significant step forward in the global fight against cancer. How do you see this shaping the future of oncology? Let’s discuss in the comments! ⬇️ story source: https://lnkd.in/dbQQxgpT #cancer #cancerresearch #coloncancer #oncology

How does ecDNA contribute to cancer treatment resistance? Extrachromosomal DNA (ecDNA) contributes to cancer treatment resistance through several mechanisms. First, ecDNA allows for rapid genomic changes, enabling cancer cells to adapt quickly to therapies, which can lead to treatment failure. The random distribution of ecDNA during cell division results in unequal inheritance of oncogenes, fostering tumor heterogeneity and variability in drug response. Additionally, ecDNA can carry genes that promote drug resistance, such as those enhancing target expression or altering signaling pathways, which further complicates treatment efficacy. This dynamic nature of ecDNA underscores its role as a critical factor in cancer progression and resistance. Sources: [1] Extrachromosomal DNA (ecDNA): an origin of tumor heterogeneity, genomic remodeling, and drug resistance https://lnkd.in/gE8rptdk [2] Study Links ecDNA in Barrett’s Esophagus with Cancer https://lnkd.in/gy2aQ2qz [3] ecDNAs are Extra Active and Terrifying https://lnkd.in/gqk7AmT2 [4] Tiny DNA circles are key drivers of cancer, Stanford Medicine-led international study finds https://lnkd.in/gPyRkG7E [5] Why Do Cancer Treatments Stop Working? - NCI https://lnkd.in/gm2Ee2qA [6] Extrachromosomal DNA (ecDNA) in cancer: mechanisms, functions, and clinical implications https://lnkd.in/gjRggUAg [7] Extrachromosomal DNA amplifications in cancer - Nature Reviews Genetics https://lnkd.in/gMtcSy8h [8] DNA Damage Response in Cancer Therapy and Resistance https://lnkd.in/ggyRJxiT

Groundbreaking Technology from KAIST Transforms Colon Cancer Treatment Exciting news from the Korea Advanced Institute of Science and Technology (KAIST)! Researchers at KAIST have developed an innovative technology that can transform colon cancer cells back into normal cells, presenting a revolutionary approach to cancer treatment. Traditionally, cancer treatments like chemotherapy and radiation aim to kill cancer cells, often causing severe side effects and risking damage to healthy cells. This new technology offers a promising alternative by reprogramming cancer cells into their normal state without the harmful effects associated with conventional treatments. Led by Prof. Cho Kwang-hyun, the team identified master molecular switches that induce the reversion of cancer cells to normal cells. This was achieved through a combination of simulation analyses and molecular cell experiments. The success of this research not only paves the way for treating colon cancer but also holds potential for application in various other cancer types. This breakthrough underscores the potential for more effective, less harmful cancer treatments, bringing hope to patients and the medical community alike. https://lnkd.in/dn-cKwkx #CancerResearch #MedicalBreakthrough #KAIST #InnovativeTreatment #CancerTreatment #MedicalScience